• Vaxil Locations
  • Contact Us
  • Subscribe
Vaxil Bio
  • About Vaxil
  • TEAM
  • INTELLECTUAL PROPERTY
  • News and Updates
  • In the Media
  • 2025 Shareholder Meeting Material

Author Archives: David Goren

28 Aug
Annnouncements

Vaxil Bio Licenses P-Esbp for Targeted Cancer Therapy from BGN Technologies, the Technology Transfer Company of Ben-Gurion University, Israel

… Read the rest
Posted on August 28, 2019April 30, 2020 by David Goren
30 Jun
Annnouncements

Q2 2019 FINANCIALS NOW AVAILABLE

… Read the rest
Posted on June 30, 2019April 30, 2020 by David Goren
21 May
Annnouncements

Vaxil Granted Significant US Patent For Anti-Infective Vaccines

… Read the rest
Posted on May 21, 2019April 30, 2020 by David Goren
31 Mar
Annnouncements

Q1 2019 Financials Now Available

… Read the rest
Posted on March 31, 2019April 30, 2020 by David Goren
02 Feb
Annnouncements

2018 Public Filings Now Available

… Read the rest
Posted on February 2, 2019April 30, 2020 by David Goren
Older posts
Newer posts

Vaxil Canada
First Canadian Place, 34th Floor, 100 King Street W., Toronto, Ontario. M2N 6N4 Canada

Vaxil Israel
3 Pinhas Sapir Street, 3rd Floor, Weizmann Science Park, 74140, Rehovot, Israel

Corporate

  • Home
  • About Vaxil
  • Vaxil Locations
  • Contact Us
  • Board & Executives
  • News and Updates

INVESTORS

  • Investor Presentations
  • Public Filings
  • News and Updates
  • In the Media
  • Video
  • Scientific Publications
Copyright 2025 © VAXIL BIO THERAPEUTICS | Vaxil Bio therapeutics is an Israeli biotech focused on cancer immunotherapy, based in the Weizmann Science Park in Rehovot, Israel. Vaxil is listed on the TSX-Venture as VXL
  • About Vaxil
  • TEAM
  • INTELLECTUAL PROPERTY
  • News and Updates
  • In the Media
  • 2025 Shareholder Meeting Material
  • Vaxil Locations
  • Contact Us
  • Subscribe